Eikon Therapeutics Reports 26.4% Response Rate for EIK1003-Paclitaxel Combination in Phase 1/2 Trial
Bitget2026/10/23 13:16- Eikon Therapeutics presented early-stage cancer trial results for EIK1003, EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress.
- EIK1003 showed antitumor activity alone and in combinations; the paclitaxel combination’s safety profile was consistent with the chemotherapy’s known toxicities.
- EIK1004 showed tumor responses with limited severe blood-related side effects; initial results from a planned docetaxel combination arm are expected in late 2027.
- EIK1005 showed disease stabilization alone and a partial response in one pembrolizumab combination participant; its drug-exposure profile supported weekly dosing.
- Additional EIK1005 combination results are expected in the first half of 2027, with complete monotherapy results due in the second half.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Europe’s largest asset manager Amundi tokenizes equity index fund on Ethereum
Apple plans to raise 7 billions USD to repurchase stocks, returning to the US dollar bond market after a year and a half.
Apple raised approximately $7 billion through this bond issuance, which is divided into seven tranches with maturities ranging from two to ten years. The longest tranche was initially priced at a spread of 80 basis points over US Treasuries. The proceeds from the bonds will be used for general corporate purposes, including stock buybacks, dividend payments, and capital expenditures. Analysts pointed out that shareholder returns are a higher priority than AI capital expenditures in Apple's capital allocation.
Crypto prices
More
